You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明巨諾-B(02126.HK)公佈中期業績:上半年收入同比升32.9%,研發開支達2.2億元
格隆匯 08-29 16:39

格隆匯8月29日丨藥明巨諾-B(02126.HK)公佈中期業績,國際財務報吿準則計量:收入由截至2022年6月30日止六個月的人民幣6600萬元增加32.9%至截至2023年6月30日止六個月的人民幣8770萬元,該增長是由於集團的靶向CD19自體嵌合抗原受體T(“CAR-T”)細胞免疫治療產品倍諾®(瑞基奧侖賽注射液(“relma-cel”),研發代碼:JWCAR029)持續商業化。倍諾®獲批准用於治療成人患者的復發或難治性(“r/r”)大B細胞淋巴瘤(“LBCL”)及r/r濾泡性淋巴瘤(“FL”)。隨着市場不斷髮展,預期倍諾®的銷售收入會繼續增加,卓越的產品特性可為患者帶來突破性價值及預期更多的適應症獲批准。

毛利由截至2022年6月30日止六個月的人民幣2310萬元增加93.9%至截至2023年6月30日止六個月的人民幣4480萬元。銷售毛利率由截至2022年6月30日止六個月的35.0%增加至截至2023年6月30日止六個月的51.1%。上述增加主要是由於成本削減計劃的實施及更多患者接受倍諾達®治療而達致規模經濟。

研發開支由截至2022年6月30日止六個月的人民幣1.959億元增加10.5%至截至2023年6月30日止六個月的人民幣2.165億元,該增加主要是由於:(i)蘇州新載體生產設施於2022年下半年投入使用,導致折舊及攤銷增加;及(ii)臨牀前研究活動及不同階段的臨牀試驗,導致研發材料以及測試及臨牀費用增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account